SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

Highlights Shin Nippon Biomedical Laboratories, Ltd. BOERSE MUENCHEN

Equities

YB3

JP3379950003

Market Closed - BOERSE MUENCHEN Other stock markets 20:43:13 03/07/2024 BST			5-day change	1st Jan Change
8 ^EUR	0.00%		-3.61%	-25.93%

05-08	Shin Nippon Biomedical Laboratories, Ltd. Announces Fiscal Year End Dividend for the Fiscal Year Ended March 31, 2024, Payable on June 25, 2024; Provides Second Quarter End and Fiscal Year End Dividend Guidance for the Fiscal Year Ended March 31, 2025	CI
05-08	Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Forecasts for the Six Months Ending September 30, 2024 and Year Ending March 31, 2025	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Shin Nippon Biomedical Laboratories, Ltd. Announces Fiscal Year End Dividend for the Fiscal Year Ended March 31, 2024, Payable on June 25, 2024; Provides Second Quarter End and Fiscal Year End Dividend Guidance for the Fiscal Year Ended March 31, 2025	05-08	CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Forecasts for the Six Months Ending September 30, 2024 and Year Ending March 31, 2025	05-08	CI
Final dividend	03-27	FA
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	02-02	CI
Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending March 31, 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending March 31, 2024	11-07	CI
Ex-dividend day for interim dividend	27/09/23	FA
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024	02/08/23	CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024	02/08/23	CI
Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting	15/06/23	CI
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.	07/06/23	CI
Shin Nippon Biomedical Laboratories, Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	08/05/23	CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024	08/05/23	CI
Shin Nippon Biomedical Laboratories, Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023	08/05/23	CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024	08/05/23	CI
Shin Nippon Biomedical to Make $30 Million Offer for US-based Satsuma Pharmaceuticals	18/04/23	MT
Satsuma Pharmaceuticals to be Acquired by Shin Nippon Biomedical	17/04/23	MT
Shin Nippon Biomedical Laboratories, Ltd. entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers for $27.6 million.	16/04/23	CI
Ex-dividend day for final dividend	29/03/23	FA
Shin Nippon Biomedical Laboratories, Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	31/01/23	CI
Shin Nippon Biomedical Laboratories, Ltd. Revises Year End Dividend Guidance for the Year Ending March 31, 2023	31/01/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Shin Nippon Biomedical Laboratories, Ltd. BOERSE MUENCHEN

Equities

YB3

JP3379950003

Highlights

Filters